Joren Maeremans

Joren Maeremans

Auto-generated profile, based on publicly available information

Joren Maeremans

Faculty of Medicine and Life Sciences, Universiteit Hasselt, Hasselt, Belgium

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2017 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
JMJoren Maeremans
Joren Maeremans
JSJames Spratt
James Spratt
PKPaul Knaapen
Paul Knaapen
SWSimon Walsh
Simon Walsh
PAPierfrancesco Agostoni
Pierfrancesco Agostoni
JDJo Dens
Jo Dens

25 October 2017 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
JMJoren Maeremans
Joren Maeremans
DVDavid Verhaert
David Verhaert
BPBruno Pereira
Bruno Pereira
PFPeter Frambach
Peter Frambach
CMCarlos Van Mieghem
Carlos Van Mieghem
JDJo Dens
Jo Dens

5 July 2021 in Acta Cardiologica
Verified
Journal Article
Closed access
DCDaan Cottens
Daan Cottens
JMJoren Maeremans
Joren Maeremans
MVMathias Vrolix
Mathias Vrolix
JLJohan Van Lierde
Johan Van Lierde
JDJo Dens
Jo Dens
BFBert Ferdinande
Bert Ferdinande
This study aimed to assess the reliability of pressure derived fractional flow reserve (FFR) measurement and the handling performance of the OptoWire Deux with an optical pressure sensor relative t...

28 November 2017 in Acta Cardiologica
Verified
Journal Article
Closed access
JMJoren Maeremans
Joren Maeremans
PKPeter Kayaert
Peter Kayaert
YBYoann Bataille
Yoann Bataille
JBJohan Bennett
Johan Bennett
CUClaudiu Ungureanu
Claudiu Ungureanu
(I(On behalf of the BWGCTO Investigators)
(On behalf of the BWGCTO Investigators)
Background: Important developments in materials, devices, and techniques have improved outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI), and resulted in a growing interest in CTO-PCI. The Belgian Working Group on Chronic Total Occlusions (BWGCTO) working group aims to assess the evolution within the CTO-PCI landscape over the next years. Methods: From May 2016 onwards, patients undergoing CTO-PCI were included in the BWGCTO registry by 15 centres in Belgium and Luxemburg. Baseline, angiographic, and procedural data were collected. Here, we report on the one-year in-hospital outcomes. Results: Over the course of one year, 411 procedures in 388 patients were included with a mean age of 64 ± 11 years. The majority were male (81%). Relatively complex CTOs were treated (Japanese CTO score =2.2 ± 1.2) with a high procedure success rate (82%). Patient- and lesion-wise success rates were 83 and 85%, respectively. Major adverse in-hospital events were acceptably low (3.4%). Antegrade wire escalation technique was applied most frequently (82%). On the other hand, antegrade dissection and re-entry and retrograde strategies were more frequently applied in higher volume centres and successful for lesions with higher complexity. Conclusion: Satisfactory procedural outcomes and a low rate of adverse events were obtained in a complex CTO population, treated by operators with variable experience levels. Antegrade wire escalation was the preferred strategy, regardless of operator volume.

6 March 2020 in Acta Cardiologica
Verified
Journal Article
Closed access
WEWard Eertmans
Ward Eertmans
IHIef Hendrickx
Ief Hendrickx
RPRuben Pauwels
Ruben Pauwels
JMJoren Maeremans
Joren Maeremans
KMKeir McCutcheon
Keir McCutcheon
JDJo Dens
Jo Dens
Background: The impact of revascularisation of chronic total occlusions (CTO) on the incidence of ventricular arrhythmias (VA) remains to be elucidated. Methods: Based on prospectively gathered data, the recurrence rate of VAs following CTO treatment was retrospectively investigated. Patients presenting with VAs as clinical indication for CTO revascularisation were retrospectively selected out of three Belgian CTO registries (i.e. Ziekenhuis Oost-Limburg, UZ Leuven and CHR de la Citadelle). Freedom of VAs was defined as absence of non-sustained or sustained tachycardias (VT), ventricular fibrillations (Vfib) and ventricular extrasystoles (VES; <2500 VES/24 h). Long-term outcome in terms of reoccurrence of VAs was evaluated by reviewing patient records. Results: Between 2011 and 2019, 912 patients underwent a CTO-PCI across three Belgian centres. In total 43 patients (5%) presented with VAs as clinical indication for CTO revascularisation. Overall follow-up was 723 (391 − 1144) days. Fourteen (33%), 18 (42%), 5 (11%) and 6 (14%) presented with >2500 VES/24 hrs, non-sustained VT, sustained VT and Vfib, respectively. In those patients with a one-year follow-up available (n = 34), overall recurrence rate of VAs was 38% (within VA group: VES: 25%, non-sustained VT: 46%; sustained VT: 25% and Vfib: 60%). Conclusion: Based on this retrospective data analysis, CTO revascularisation, in patients presenting with VAs as the main clinical indication, seems to beneficially impact the incidence of VAs, which ultimately might result in improved patients’ outcome.